Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 1997

View Archived Issues

ET antagonists from Warner-Lambert claimed for cerebrovascular disorders

MS&D describes tachykinin antagonists

Factor Xa inhibitors from 3-D

Antiischemic potassium channel activators described by BMS

3-D describes potent and selective thrombin inhibitors

MS&D discloses 5-HT1-like receptor agonists

Glutamate antagonists from Warner-Lambert

Pharmacokinetics and tissue distribution of TOP-53

Nippon Shinyaku characterizes novel sulfonamide antitumor agent

Phase I/II results for Glaxo's tucaresol in metastatic melanoma

FDA approves Columbia's Crinone

PAK-104P reverses both P-glycoprotein- and MRP-mediated MDR

Potent, selective, orally active tachykinin NK1 antagonist reported by Menarini

New hypoxic cytotoxin from Evanston Hospital

Cellegy: Q1 1997 highlights

Interneuron: Q2 1997 highlights

Connetics: Q1 1997 highlights

NeoRx: Q1 1997 highlights

Dusa: Q1 1997 highlights

FDA advisory committee recommends Roche's Xenical for weight loss

Cytogen updates stockholders

Elan to market Dainippon's zonisamide in North America

SmithKline Beechan to market Kissei's tranilast

Discovery licenses N-0923 transdermal patch to Yoshitomi

NeoPharm licenses broxuridine to BioChem Therapeutic

Innovative Technologies and Derma Sciences form strategic joint venture

Receptagen receives offer to merge from Generex

Cephalon and Chiron seek European approval of Myotrophin

BMS and RTI form anticancer alliance

Mouse model for idiopathic voiding disorders in humans

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...